ImmuCell (ICCC) reported preliminary Q4 sales late Thursday of $7.8 million, up from $5.1 million a year earlier.
The full-year total sales stand at $26.5 million, up from $17.5 million in 2023, according to the company.
Analyst estimates were not available for comparison.
ImmuCell said its annualized production for the quarter ended Dec. 31 was about 103% of estimated full capacity and helped reduce its orders backlog to $4.4 million as of Jan. 1, from $9.4 million as of Jan. 1, 2024.